FA
TEVA icon

Financial Advantage’s Teva Pharmaceuticals TEVA Stock Holding History

Financial Advantage’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,100
Closed -$44K – 188
2013
Q4 		$44K Sell
1,100
-123,502
-99% -$4.86M 0.04% 79
2013
Q3 		$4.71M Buy
124,602
+726
+0.6% +$28.3K 4.06% 10
2013
Q2 		$4.86M Buy
+123,876
New +$4.82M 4.22% 10

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
SFM
Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Financial Advantage's TEVA Position: Q1 2014 in Review

Financial Advantage sold out of Teva Pharmaceuticals (TEVA) in Q1 2014, closing a stake of 1,100 shares — an estimated $44K sold.

Financial Advantage first reported a position in TEVA in Q2 2013 and held it in 3 quarters. The position peaked at $4.86M in Q2 2013. 770 funds tracked by Wall St. Rank hold TEVA as of Q1 2014.

  • Financial Advantage reported no remaining Teva Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Financial Advantage sold 1,100 Teva Pharmaceuticals shares in Q1 2014, an estimated $44K.
  • Financial Advantage first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Financial Advantage's Teva Pharmaceuticals position peaked at $4.86M in Q2 2013.
  • 770 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2014.

Based on Financial Advantage's 13F filing for Q1 2014, filed 9 May 2014.